Halozyme Therapeutics Elects James Daly to Board

What Happened

• Halozyme Therapeutics (HALO) filed an 8-K (Item 5.02) reporting that James Daly was elected to the company’s Board of Directors on September 28, 2026.
• Mr. Daly was elected to the class of directors with a term that expires at Halozyme’s annual meeting of stockholders in 2029. He was not initially assigned to any Board committee.

Key Details

• Election date: September 28, 2026; 8-K filing date: September 30, 2026.
• Term length: position runs until the 2029 annual meeting.
• Compensation: Mr. Daly will be paid under Halozyme’s non-employee director compensation program (cash retainers, restricted stock and stock option awards), as described in Halozyme’s proxy for the May 5, 2026 annual meeting.
• No special arrangements or understandings led to his election, and there are no related-person transactions between Mr. Daly and the company.

Why It Matters

• This is a board composition change that investors should note because board membership can influence governance and strategic oversight.
• The filing indicates standard director compensation and no related-party transactions, which reduces potential conflict-of-interest concerns.
• There are no other material financial or management disclosures in this 8-K, so immediate operational or financial impact on Halozyme is not indicated.